CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On December 9, 2019, the new CTS Laboratory Information System successfully implemented in Phoe...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...
That’s just one of the reasons that National Blood Donor Month, which has taken place each Jan...
We have now added a new section called the "Assay History List" to the "At A Gla...
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...